TytoCare Secures $25M Funding and Appoints Adam Pellegrini as CEO

TytoCare, a leader in remote physical examination technology, has announced two significant developments: the appointment of Adam Pellegrini as CEO and the successful closure of a growth round exceeding $25 million. This funding round, led by Insight Partners and supported by other notable investors, positions TytoCare to enhance its AI-driven platform aimed at transforming virtual primary care, particularly for patients with chronic and complex diseases. This strategic pivot to an AI-first clinical enablement model is designed to bridge the existing gap between in-person clinical rigor and virtual care delivery, particularly in areas such as cardiopulmonary and oncology care.

Pellegrini, who brings over 20 years of experience in digital health and consumer technology, will guide TytoCare as it integrates its remote examination platform with FDA-cleared AI-powered software. This integration is critical for enhancing the quality of virtual care, allowing clinicians to conduct comprehensive remote physical exams with a level of diagnostic confidence that was previously limited to in-person visits. TytoCare’s platform includes a handheld examination device capable of capturing clinical-grade data across various bodily systems, supported by AI algorithms that continuously improve as new evidence emerges.

The recent funding round, which was oversubscribed, signals strong institutional confidence in TytoCare’s market position and the growing demand for AI-enabled remote diagnostics. The capital raised will be directed toward expanding the company’s pipeline of clinical algorithms, strengthening partnerships with health systems and payers, and accelerating market entry efforts targeting chronic disease populations. Key areas of focus will include managing conditions such as congestive heart failure, chronic obstructive pulmonary disease, and oncology treatment monitoring.

Insight Partners’ Managing Director, Jeff Horing, emphasized the unique combination of TytoCare’s FDA-cleared exam device and its AI algorithms, which address the longstanding challenge of diagnostic fidelity in home care. This combination not only enhances the quality of care but also creates a defensible market position as health systems increasingly seek to extend clinical services into patients’ homes. Pellegrini’s leadership is expected to drive the integration of TytoCare’s capabilities into the workflows of health systems and payer-sponsored chronic disease management programs.

As TytoCare advances its clinical enablement strategy, the company aims to close the clinical fidelity gap that has historically limited the effectiveness of telehealth solutions for complex patient populations. With Pellegrini at the helm, TytoCare is poised to leverage its technology to become a vital partner for health systems looking to enhance their remote care offerings. The appointment of Greg Orr as COO, who has a strong background in digital health, further strengthens the leadership team as they pursue this ambitious vision.

Looking ahead, TytoCare’s strategic focus on embedding AI-assisted examination capabilities into existing care workflows could significantly alter the competitive landscape in telehealth. As health systems increasingly adopt these advanced technologies, the demand for integrated remote care solutions is likely to rise, creating opportunities for TytoCare to establish itself as a leader in the market. The company’s ability to deliver high-quality, AI-powered diagnostics directly to patients at home may redefine standards of care in chronic disease management, setting a new benchmark for virtual healthcare delivery.